-+ 0.00%
-+ 0.00%
-+ 0.00%

Milestone Pharmaceuticals study finds PSVT curbs daily activities, drives anxiety between episodes

PUBT·08/27/2026 12:00:51
Listen to the news
Milestone Pharmaceuticals study finds PSVT curbs daily activities, drives anxiety between episodes
  • Milestone Pharmaceuticals flagged new longitudinal study findings on how PSVT affects daily life between episodes.
  • Results will be presented Aug. 30, 2026 at the European Society of Cardiology Congress 2026 in a moderated ePoster session.
  • Patient-reported data showed sustained quality-of-life burden between episodes, with frequent activity disruption, avoidance behaviors, sleep or work dissatisfaction.
  • Persistent anxiety between episodes emerged as a recurring issue, reinforcing that impact extends beyond acute events.
  • Chronic medication side effects were commonly viewed as burdensome, supporting the case for alternative at-home episode-termination options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270800PRIMZONEFULLFEED9816806) on August 27, 2026, and is solely responsible for the information contained therein.